Achiko Establishes Medtech Expert Advisory Board and Expands Management Team

• New international advisory board members: Mr
  Glenn Cross (Australia), Dr Jittaporn Wattanaseree (Thailand) and Ms Carol Aebi
  (Switzerland)
• Management team appointment: Mr Pierre
  Nathie of Med2Mark as VP, Commercialisation

ZURICH, SWITZERLAND – EQS Newswire – 13 October 2020 – Achiko AG (SWX:ACHI, ISIN CH0522213468) is pleased
to announce an update to its management and advisory team.

As progress continues towards the launch of Achiko’s Covid-19 test kit led
by a world-class research and development team, the Company has established
an advisory board of international experts in the medtech, biotech and
innovation fields and appointed a head of commercialisation, effective
immediately, as it prepares for global expansion.

Advisory Board

– Mr Glenn Cross is Director at leading tech and
healthcare companies Horizon 3 Biotech, Captix Biomedical, and Grey Innovation.
He will join Achiko’s Board of Directors later this year.

– Dr Jittaporn Wattanaseree is a lecturer and
trainer experienced in the pharmaceutical and biopharmaceutical fields over all
stages of drug development from research through commercialisation.

– Ms Carol Aebi is a Strategist and the Head of
Business Analysis at Swiss software engineering firm AdNovum.

Management Appointment

– Mr Pierre Nathie joins Achiko’s existing management team
as the Vice President, Commercialisation. Currently the Managing Director of
Med2Mark, an international consulting firm specialising in the
commercialisation of health-tech innovations, Pierre brings to Achiko 25+
years’ experience in launching of innovative medtech and biotech products and
solutions in international markets.

“We’re excited about the progress with Gumnuts, working with
Regenacellx.sL, the novel covid testing technology. We recognise that to make
this a success, the company needs to broaden its expertise and execution
capability and we’re excited to be joined by Glenn, Dr Jittaporn, Carol and
Pierre,” said Steven Goh, Achiko CEO.

“We’ve started clinical evaluation trials and we’re updating our
regulatory strategy to broaden our footprint. Unlike the more popular PCR and
Antigen approaches, our differentiated approach has a supply chain that offers
an alternative to resolving capacity issues with testing, as well as a likely
friendly patient experience and a cost profile that other testing approaches
have yet to meet.”

“Strengthening our board and management team, is about getting to
market with the right level of care and diligence, and in a timely
manner.”

About Achiko AG

Headquartered in Switzerland, with a global market focus, Achiko AG
(SWX:ACHI, ISIN CH0522213468) is an entrepreneurial platform company, utilising
the knowledge and experience of its people and key technologies to enable
transformation in various industries.

Through innovations in technology and regulation along with the company’s
unique operating footprint from Europe to Asia, Achiko seeks to transform
markets and bring unique value to its customers, people, and shareholders.
Achiko’s core platform consists of user registration and payment services which
are accessible to application developers. A messaging service and other
community based social features are being launched in late 2020. Achiko
supports innovations in healthcare through its Teman Sehat (“Health
Buddy”) ecosystem, a novel testing technology being developed with
Regenacellx.sl, as well as consumer payments and finance and games and
entertainment.

For any inquiries regarding Gumnuts or Teman Sehat, please contact info@achiko.com

Further information about Achiko can be found at https://www.achiko.com

Further information about the Teman Sehat ecosystem can be found at https://www.temansehat.co

Further information about Regenacellex.sl can be found at https://regenacellx.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Achiko AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors, which could
cause the actual results, financial condition, performance or achievements of
Achiko AG to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Achiko AG
is providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.